> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Q&A: Daye launches at-home hormone testing service across the UK
- URL: https://med-techinsights.com/qa-daye-launches-at-home-hormone-testing-service-across-the-uk/
- Published: 2025-08-28T15:00:00.000Z
- Updated: 2026-10-23T02:33:00.000Z
- Description: Daye has just launched a comprehensive at-home hormone testing service across the UK, and Med-Tech Insights spoke to Valentina Milanova, founder & CEO of Daye to find out more. 1. What specific hormones does the at-home test measure, and how do these results help identify conditions like PCOS?Daye’s
- Author: Olivia Friett
- Tags: Insights, Femtech

**Daye has just launched a comprehensive** [**at-home hormone testing service**](https://www.yourdaye.com/products/hormone-test/?srsltid=AfmBOoowjva0DLgJyJKdlTE74QgE73DILQ-FqkmSatngHm%5FMlmRNkiOb&ref=med-techinsights.com) **across the UK, and Med-Tech Insights spoke to Valentina Milanova, founder & CEO of Daye to find out more.**

**1\. What specific hormones does the at-home test measure, and how do these results help identify conditions like PCOS?**  
Daye’s hormone testing service is available in two versions. The Basic Hormone Panel measures eleven biomarkers, including key reproductive hormones such as Follicle-Stimulating Hormone (FSH), Luteinising Hormone (LH), Oestradiol, Prolactin, Total Testosterone, Sex Hormone-Binding Globulin (SHBG), and the calculated Free Androgen Index, alongside thyroid hormones (TSH and Free Thyroxine) and two nutritional markers that are vital to hormonal health – Vitamin D and Ferritin – a marker of iron levels. The Advanced Fertility Panel includes all of these and adds Anti-Müllerian Hormone (AMH), a highly sensitive measure of ovarian reserve.

In the context of PCOS, this panel provides a complete hormonal picture in a single test. Many individuals with PCOS present with an elevated LH-to-FSH ratio, reflecting disrupted follicular development. Hyperandrogenism, evidenced by raised total testosterone or an elevated Free Androgen Index, is one of the core diagnostic criteria and underpins many of the hallmark symptoms, from acne to hirsutism. Oestradiol measurements help assess ovulatory function and luteal phase adequacy, while prolactin is checked to rule out hyperprolactinaemia, a separate condition that can also cause irregular cycles. Thyroid function is included because hypothyroidism can mimic or exacerbate PCOS symptoms. Vitamin D and ferritin levels are assessed because deficiencies in these nutrients are common in PCOS and have been linked to poorer reproductive, metabolic, and mood outcomes. Bringing all these parameters together in a single, high-quality sample reduces the need for fragmented and delayed testing across multiple appointments.

**2\. Can you explain in more detail how the upper-arm Tasso+ blood collection technology works, and how it compares to traditional tests in terms of accuracy?**  
The upper-arm device we use is CE-marked and employs a gentle vacuum-assisted mechanism coupled with a microneedle to collect capillary blood from the upper arm. The device adheres comfortably to the skin (its size and profile are similar to a continuous glucose monitor) and is activated at the press of a button. Because the collection site is on the upper arm, away from fingertip nerve endings, the process is virtually pain-free and has a much lower risk of triggering vasovagal reactions.

In terms of accuracy, this method has several advantages over traditional finger-prick sampling. It collects a larger volume of blood, which is essential for running a comprehensive hormone panel without risking dilution or insufficient sample volume. The design minimises patient error by eliminating the squeezing and repeated lancing often associated with finger-pricks, which can cause haemolysis and compromise sample quality. The collected blood is stabilised immediately in the tube, preserving the integrity of hormones for analysis. All samples are processed in UKAS-accredited laboratories using the same methods applied to venous blood draws in clinics, ensuring equivalent sensitivity, specificity, and reproducibility to in-clinic tests.

**3\. How quickly can users expect to receive their results, and how are these results communicated?**  
Once the sample has been collected and returned to our partner laboratory, patients can expect results within three to five working days. The results are delivered securely via the patient’s Daye health dashboard and come with a detailed clinical interpretation. This interpretation not only lists each biomarker’s value and reference range, but also explains whether the result sits above, below, or within optimal parameters and what that might mean in the context of the patient’s symptoms, menstrual cycle phase, and overall health profile. The service also includes the option for follow-up consultations with Daye’s clinical team, including gynaecology-specialist nurses and nutritionists, so that results are not left as raw data but are transformed into actionable next steps, whether that means lifestyle adjustments, supplementation, or referral for further medical assessment.

**4\. What role do you see this technology playing in reducing the 7–10 year diagnostic delay for PCOS?**  
The average time to diagnosis for PCOS remains between seven and twelve years, a delay that stems from fragmented care pathways, limited early access to testing, and the absence of integrated interpretation across hormonal, metabolic, and imaging findings. Traditionally, patients may have to attend multiple GP appointments over months or years to build up a complete hormonal picture, and tests are often ordered only after prolonged symptom persistence.

By contrast, Daye’s at-home service allows patients to initiate a full hormonal evaluation at the first sign of concerning symptoms, whether they be irregular cycles, sudden weight changes, acne, or hirsutism, without waiting for referral or scheduling delays. The device captures all relevant reproductive, thyroid, and nutritional biomarkers in one painless, high-quality sample, removing the need for repeat blood draws. Importantly, results are interpreted in the context of the patient’s symptoms and medical history, and linked to tailored advice, which means that abnormal findings can be acted on promptly. Over time, this model could significantly compress the diagnostic timeline, reducing it from a decade. By placing accurate, comprehensive hormonal assessment in the hands of patients early, we shift from reactive to proactive diagnosis, addressing one of the main structural causes of PCOS diagnostic delay.